SequelSEC

BIODESIX INC BDSX

Services-Medical Laboratories · CIK 0001439725 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$26.86M
Fiscal year ended 2026-06-30
Operating income
-$5.39M
Fiscal year ended 2026-06-30
Free cash flow
-$1.76M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$19.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.99Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Medical Laboratories filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%6th
R&D / revenue13.6%25th
FCF margin-26.6%29th
Revenue YoY growth24.1%70th
Net margin-39.8%33th
SBC / revenue4.7%35th
Operating margin-31.5%38th
Current ratio1.86x44th

BIODESIX INC (BDSX) reported revenue of $26.86M and net income of -$7.27M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BIODESIX INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

BIODESIX INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$26.86M$25.56M$28.76M$21.77M$20.02M$17.96M$20.43M$18.15M$17.92M$14.82M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$5.39M-$6.20M-$1.97M-$7.05M-$9.72M-$9.14M-$6.65M-$8.59M-$8.24M-$11.02M
Net income-$7.27M-$7.79M-$3.98M-$8.72M-$11.47M-$11.10M-$8.25M-$10.26M-$10.81M-$13.61M
Research & development$3.14M$3.28M$2.87M$2.99M$3.27M$2.87M$2.41M$2.55M$2.56M$2.04M
Weighted-average diluted sharesshares 10.30Mshares 9.66MUnavailableshares 7.50Mshares 7.33Mshares 7.30MUnavailableshares 7.32Mshares 127.17Mshares 97.17M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-0.71$-0.81Unavailable$-1.16$-1.56$-1.52Unavailable$-1.40$-0.08$-0.14
Selling, general & administrative$24.28M$24.26M$22.97M$21.71M$22.41M$20.45M$20.22M$20.02M$19.66M$20.56M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketing$2.24M$2.21M$1.96M$1.75M$1.98M$1.87M$1.52M$1.62M$2.29M$2.15M

Balance

BIODESIX INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$30.00M$25.57M$18.99M$16.60M$20.73M$17.60M$26.24M$31.41M$42.22M$11.49M
Total assets$95.33M$94.64M$87.48M$88.72M$87.74M$86.24M$97.24M$102.74M$115.84M$87.20M
Current assets$43.56M$40.91M$32.52M$33.40M$32.44M$29.62M$39.48M$44.02M$57.58M$28.48M
Total liabilities$86.18M$85.50M$89.94M$90.44M$86.60M$75.18M$76.37M$74.89M$79.58M$92.70M
Current liabilities$15.29M$14.49M$17.44M$18.15M$15.16M$13.32M$14.32M$12.96M$17.55M$31.23M
Total equity incl. NCI$9.14M$9.13M-$2.46M-$1.72M$1.14M$11.06M$20.88M$27.86M$36.26M-$5.50M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$9.11M$9.50M$9.04M$12.67M$7.45M$7.64M$8.60M$8.04M$10.13M$9.89M
Goodwill$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M$15.03M
Long-term debt$50.00M$50.00M$50.01M$50.01M$50.02M$40.02M$40.03M$40.04M$40.05M$40.06M
Accounts payable$2.16M$3.65M$3.08M$3.62M$2.97M$2.92M$2.19M$2.54M$2.22M$3.21M

Cash flow

BIODESIX INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.56M-$10.17M$778.00K-$8.88M-$6.57M-$8.60M-$4.10M-$10.67M-$18.57M-$15.31M
Capital expenditures$197.00K$81.00K$86.00K$48.00K$51.00K$74.00K$839.00K$231.00K$1.93M$234.00K
Investing cash flow-$254.00K-$144.00K-$104.00K-$67.00K-$95.00K-$137.00K-$884.00K-$286.00K-$2.00M-$273.00K
Financing cash flow$6.24M$16.90M$1.71M$4.82M$9.79M$97.00K-$181.00K$144.00K$51.30M$791.00K
Net change in cash$4.42M$6.58M$2.38M-$4.12M$3.13M-$8.64M-$5.16M-$10.81M$30.73M-$14.79M
Stock-based compensation$820.00K$1.12M$1.08M$1.05M$1.04M$972.00K$1.26M$1.52M$1.22M$2.64M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.39M$1.40M$1.39M$1.41M$1.44M$1.44M$1.45M$1.49M$1.41M$1.42M

Derived

BIODESIX INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$1.76M-$10.25M$692.00K-$8.93M-$6.62M-$8.68M-$4.94M-$10.90M-$20.50M-$15.54M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-20.1%-24.3%-6.8%-32.4%-48.6%-50.9%-32.5%-47.3%-46.0%-74.4%
FCF margin-6.5%-40.1%2.4%-41.0%-33.1%-48.3%-24.2%-60.1%-114.3%-104.9%
SBC / revenue3.1%4.4%3.7%4.8%5.2%5.4%6.2%8.3%6.8%17.8%
Current ratio2.85x2.82x1.86x1.84x2.14x2.22x2.76x3.40x3.28x0.91x
Revenue YoY growth34.2%42.3%40.8%19.9%11.7%21.2%39.3%34.5%51.0%63.6%
Net margin-27.1%Unavailable-13.8%-40.0%-57.3%Unavailable-40.4%-56.5%UnavailableUnavailable
R&D / revenue11.7%12.9%10.0%13.7%16.3%16.0%11.8%14.0%14.3%13.8%
CapEx / revenue0.7%0.3%0.3%0.2%0.3%0.4%4.1%1.3%10.7%1.6%
Long-term debt / equity5.47xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDSX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.